Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome.

Authors :: Morimoto M
Shimakawa S
Hashimoto T
Kitaoka T
Kyotani S
Source :: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2018 Aug; Vol. 43 (4), pp. 571-573. Date of Electronic Publication: 2017 Dec 18.
Publication Year :: 2018
Abstract: What Is Known and Objective: Dravet syndrome (DS) is an intractable epilepsy syndrome. The three-drug combination therapy of sodium valproate (VPA), clobazam (CLB) and stiripentol (STP) is recommended worldwide.<br />Case Summary: We present a case of DS, in which treatment with CLB could not be continued because of the appearance of adverse reactions to it. Replacement with topiramate (TPM) proved to be markedly effective.<br />What Is New and Conclusion: It is suggested that combination therapy with VPA, TPM and STP is for DS epilepsy.<br /> (© 2017 John Wiley & Sons Ltd.)

Subjects :: Child, Preschool
Dioxolanes adverse effects
Dioxolanes therapeutic use
Drug Therapy, Combination methods
Epilepsy drug therapy
Female
Fructose adverse effects
Fructose analogs & derivatives
Fructose therapeutic use
Humans
Topiramate
Valproic Acid adverse effects
Valproic Acid therapeutic use
Anticonvulsants adverse effects
Anticonvulsants therapeutic use
Epilepsies, Myoclonic drug therapy

Full Text Access

Tools